v3.25.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Fair Value, Assets and Liabilities
December 31,December 31,
Level20252024
Guaranteed investment certificates1$13,114 $66,584 
Trading securities1543 724 
Contingent consideration:3
Current portion$18,380 $— 
Long-term portion9,333 22,910 
$27,713 $22,910 
Business Combination, Contingent Consideration
Fair Value
Balance at December 31, 2024$22,910 
Additions233 
Change in fair value4,570 
Balance at December 31, 2025$27,713 
Schedule of Accounts Receivable
December 31,
202520242023
Accounts receivable$22,203 $23,816 $40,171 
Allowance for doubtful accounts$188 $774 $1,216 
Goodwill, Sensitivity of Fair Value
The below table illustrates the discount rate and exit multiple sensitivity to the fair value of the diagnostic reporting unit goodwill when performing the goodwill impairment analysis as of November 30, 2025. In the annual goodwill impairment analysis as of November 30, 2025, the diagnostic reporting unit utilized a 14% discount rate with an exit multiple of one.
Exit Multiple
Discount Rate0.800.901.001.101.20
13%$208,132 $217,464 $226,796 $236,128 $245,460 
14%205,252 214,254 223,256 232,258 241,259 
15%202,501 211,188 219,875 228,562 237,249 
16%199,868 208,254 216,640 225,025 233,411 
17%197,339 205,436 213,533 221,630 229,726 
Disaggregation of Revenue by Product and Geographic Area The following table represents total net revenues by product line:
For the Years Ended December 31,
202520242023
HIV$49,802 $60,804 $60,823 
Sample Management Solutions (1)
38,356 51,046 54,274 
HCV13,759 14,024 12,871 
Other product and services revenues (2)
4,648 3,506 2,265 
Risk Assessment Testing (3)
1,866 8,354 9,736 
COVID-19 (4)
624 45,172 257,779 
Molecular Services— 1,705 4,474 
Net product and services revenues$109,055 $184,611 $402,222 
Non-product and services revenues (5)
5,966 1,216 3,250 
Net revenues$115,021 $185,827 $405,472 
(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.
(2) Includes Syphilis revenues.
(3) Includes substance abuse testing product revenues.
(4) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.
(5) Includes funded research and development contracts, royalty income and grant revenues.
The following table represents total net revenues by geographic area, based on the location of the customer:
For the Years Ended December 31,
202520242023
United States$78,252 $139,161 $361,660 
Africa23,993 32,745 29,254 
Europe7,393 8,424 8,111 
Other regions5,383 5,497 6,447 
$115,021 $185,827 $405,472 
Schedules of Concentration of Risk, by Risk Factor The following table represents customer concentration risk:
For the Years Ended December 31,
Net Revenues20252024
Non-commercial customer N/A24%
December 31,
Accounts Receivable20252024
Commercial customer 15%10%
Schedule of Deferred Revenue
The following table represents deferred revenue recognized:
For the Years Ended December 31,
Deferred Revenue Recognized20252024
Accrued at beginning of year$2,484 $3,680 
Schedule of Earnings Per Share, Basic and Diluted
For the Years Ended December 31,
202520242023
Net (loss) income$(68,731)$(19,500)$53,655 
Weighted average shares of common stock outstanding:
    Basic73,485 74,434 73,348 
Dilutive effect of stock options, restricted stock, and performance stock units— — 1,041 
    Diluted73,485 74,434 74,389 
Loss (earnings) per share:
     Basic$(0.94)$(0.26)$0.73 
     Diluted$(0.94)$(0.26)$0.72 
Schedule of Accumulated Other Comprehensive Income (Loss)
Change in accumulated other comprehensive loss by component is listed below:
Foreign CurrencyTotal
Balance at December 31, 2024$(24,360)$(24,360)
Other comprehensive gain5,956 5,956 
Balance at December 31, 2025$(18,404)$(18,404)